Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

NCT01992276 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Due to preliminary efficacy results from an influenza challenge trial

Conditions

Influenza

Interventions

BIOLOGICAL: CR8020
BIOLOGICAL: CR6261
BIOLOGICAL: Placebo

Sponsor

Crucell Holland BV

Collaborators

[object Object]
[object Object]